|
|
January 2009 Issue Journey to a New Life: A Nutrition Support Case Study Hospitalized with a bowel obstruction and later enduring severe complications, Hank’s future appeared bleak. Would his care team’s efforts and his own strength of spirit be enough to restore his health? Hank’s* story is one of the most memorable of my career. He was admitted to the hospital in May of one year with a bowel obstruction due to an ileal stricture. I provided his nutrition care for 13 months, during which time we encountered significant complications, including short-bowel syndrome, enterocutaneous fistulae, and parenteral nutrition-associated liver disease (PNALD). Some of the healthcare team members thought he would not survive—but he surprised us. Background: Enterocutaneous Fistula Parenteral nutrition (PN) has traditionally been the most common form of nutrition support for patients with an enterocutaneous fistula. It is more often needed for high-output fistulae or those originating in the pancreas, jejunum, or ileum. Enteral nutrition (EN) is preferred over PN and can be done proximal or distal to some enterocutaneous fistulae, depending on the location. EN and oral diet can be used in patients who have enterocutaneous fistulae with low output, for fistulae located in the distal ileum or colon, and in situations in which a feeding tube can be advanced distal to a proximally located fistula. Fistuloclysis is the insertion of a feeding tube directly into an enterocutaneous fistula. This method is used for EN when a fistula is not expected to close on its own.3 Intestinal fluids contain water, electrolytes, protein, and other nutrients in varying amounts, depending on the location in the gastrointestinal tract. These losses are controlled with medications (see Table 1) and can be replaced in several ways, such as through intravenous fluids, oral intake, EN, and PN. Enterocutaneous fistula output can also be reinfused into another enterocutaneous fistula by fistuloclysis or into a jejunal feeding tube.1-3 Initial Hospitalization At the time of his discharge, Hank had an open abdominal wound and four enterocutaneous fistulae that were draining approximately 250 milliliters per eight-hour shift. Nurses adhered an ostomy bag to his abdomen to collect the fluid. Hank was nil per os (npo) except for ice chips and sips of water. We had adjusted his PN to a 12-hour nocturnal cycle a few days prior to discharge. PN provided 1,800 calories from 265 grams of dextrose, 100 grams of amino acids, 250 milliliters of 20% lipid, and 1.8-liter volume, with standard vitamins, minerals, and trace elements and additional sodium, chloride, and acetate. Jejunal and ileal fluid contains approximately 100 to 120 milliequivalents of sodium, 10 milliequivalents of potassium, 50 to 70 milliequivalents of bicarbonate, and 50 to 60 milliequivalents of chloride per liter.2 Our knowledge of these amounts, as well as the patient’s blood levels, helped us determine what and how much to add to his PN solution. Home PN After two weeks, Hank’s wife reported that he weighed 120 pounds, 10 pounds less than his hospital weight. We increased the dextrose content of the PN to 325 grams so that it provided a total of 2,005 calories per day. Over the next two weeks, Hank complained of dry mouth and thirst, his urine output was only 600 milliliters per day, and the ratio of blood urea nitrogen (BUN) to creatinine (Cr) had increased. Recognizing these signs of dehydration, we increased the PN volume to 2.6 liters per day. We also added extra zinc (for a total of 10 milligrams per day), as zinc is lost via gastrointestinal drainage, increasing the risk of deficiency.4 Hank’s urine output soon improved to more than 1 liter per day, and his weight stabilized. After several more weeks, the home nurse reported that Hank had jaundice and developed a fever of 102˚F, and his wife said that his eyes appeared yellowish and he was spending much time sleeping. Lab reports showed elevated alkaline phosphatase (Alk Phos), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (t bili), which raised concern for liver dysfunction. A liver biopsy result was consistent with hepatic cholestasis. Since manganese and copper are excreted primarily via the biliary route, both can reach toxic levels in severe cholestasis. We omitted manganese and decreased copper to only 0.3 milligrams from the standard 1 milligram per day.4 Second Hospitalization Elevations of serum AST, ALT, Alk Phos, and t bili can occur as early as two weeks into PN use. PNALD is still poorly understood. Etiologies include overfeeding of PN dextrose and/or lipid; continuous, rather than cyclic, PN infusion; sepsis; small-bowel bacterial overgrowth; poor bile flow due to a lack of enteral stimulation; deficiency of choline and possibly carnitine, nutrients not normally supplied in PN; and possibly the significant phytosterol content of soybean oil-based lipid emulsions. In severe, prolonged PN-associated cholestasis, liver failure and death can occur.5 The medical team held PN for six weeks, during which time we employed various other methods to nourish Hank. We added multivitamins and trace elements to his intravenous fluids, which consisted of 5% dextrose with half normal saline. Because of his symptoms of short-bowel syndrome, short transit time, and high fistula output, we used short-bowel diet guidelines to help maximize his nutrient absorption.6 Hank ate small amounts of a low-sugar diet and drank oral rehydration solution and a pediatric electrolyte drink made more palatable by adding a small amount of a sugar-free flavored drink mix. Enterocutaneous fistula output fluctuated from 1,100 to 2,400 milliliters per day and worsened with increased oral intake. The healthcare team initiated EN via fistuloclysis at 10 to 20 milliliters per hour with a goal of 45 milliliters per hour via a proximal jejunal fistula to supplement Hank’s oral intake. We chose an elemental formula because of the likelihood of poor digestion due to the lack of pancreatic and biliary secretions with feeding directly into the midjejunum. Fistuloclysis can be effective for EN if there is sufficient bowel distal to the feeding site; however, in this case, it resulted in increased distal fistula output.3 We then tried the nasogastric route to use the bowel proximal to the fistulae. Despite these efforts, as we advanced the EN rate, the patient’s fistula output increased to 3 liters per day. Ileostomy output stopped, as the intestinal fluid drained from the fistulae proximal to it. A fluoroscopic small-bowel follow-through test revealed a 15-minute transit time from the stomach to a midjejunal fistula. The team discontinued EN, nourishing Hank only by oral diet, oral rehydration solution, and intravenous fluids. He became progressively weaker, and his weight declined to 105 pounds. I remember noticing the weakness in his voice during that time. Some thought he would pass away from either starvation, sepsis, or liver failure (if we resumed PN). Out of options, we resumed PN in mid-October at less than 1,000 total calories and 70 grams of protein per day with minimal intravenous lipid (less than 0.5 grams per kilogram of body weight), and Hank was discharged. Second Period of Home PN Hank still had a long way to go. Continued fistula drainage precluded oral intake. PNALD limited our ability to safely increase PN calories. Fortunately, the low-calorie PN maintained his weight and strength, and the abdominal wound healed remarkably well. Soon, he would be ready for surgery to repair his bowel. We all hoped that eventually he would be able to eat normally again. Third Hospitalization Third Period of Home PN and Weaning to Oral Diet In mid-January, Hank weighed 100 pounds in the clinic. We increased the dextrose in the PN for a total of 1,720 PN calories per day, hoping he would gain weight. But during the following weeks, Alk Phos, ALT, and AST again rose above normal, and once more we had to decrease calories. We also added 100 milligrams of L-carnitine per day. Carnitine has not been proven beneficial in adults with PNALD, but it was reasonable to use, as patients dependent on PN are at risk for deficiency.5,7 In April, serum selenium was below normal, copper levels were normal, and whole blood manganese was elevated. We increased selenium to 80 micrograms per day and omitted manganese. In early May, the surgeon approved the advancement of oral intake with short-bowel diet precautions. An estimated 190 centimeters of small bowel and most of the colon remained, enough for full rehabilitation.6 Hank started with a diet low in simple sugars and advanced gradually to a nonrestricted diet. His progress was slow. He had little appetite, likely because he had not eaten for so long. During weekly phone calls, we discussed his intake and food choices. As oral intake improved, the ileal fistula output increased to about 50 to 100 milliliters per day. This amount was acceptable; according to his surgeon, the remaining fistula was now functioning similarly to a diverting ileostomy. Hank described his bowel movements as normal and regular. When I asked how he was feeling, Hank typically replied, “Could be better, could be worse.” Besides answering my clinical questions, he would tell me about his favorite foods, some of his activities, and, most encouragingly, his weight gain. He also told a good joke at the end of nearly every conversation. Hank gained 1 pound per week for a three-week period; after that, his weight increased more quickly. By the time he reached 110 pounds in early July, we decreased the PN macronutrients but kept fluid volume the same because of persistent elevation in his BUN/Cr ratio and inadequate oral fluid intake. After two more weeks, to further wean, we changed Hank’s PN regimen to every other night. His oral fluid intake improved, his weight increased to 114 pounds, and after that week, we finally discontinued PN. Because of Hank’s age and surgical history, I recommended vitamin B12 monitoring, although patients with terminal ileal resections of less than 20 centimeters have been found not to be at greater risk for B12 deficiency.8 His vitamin B12 level was within normal range three months after we discontinued PN. Positive Outcome Working concurrently in the areas of acute care, outpatient clinic, and home health, RDs have the opportunity to provide nutrition plans and follow patients’ progress for months, even years. I’ll never forget Hank and the long journey our team took with him, all that we learned, his tenacity and positive outlook, and the trust he had in his healthcare team. Most of all, I will never forget his enduring smile. — Theresa A. Fessler, MS, RD, CNSD, is a nutrition support specialist at the University of Virginia health system in Charlottesville and a freelance writer. * Name is fictitious. The Patient’s Perspective Every morning, the good doctor and a battery of medical persons would visit me and ask questions. I would ask, “What kinds of experiments are you going to perform now?” The doctor would smile and say, “None.” My inspiring nutritionist helped keep me alive while I was a patient there for what seemed like a million years. She would come into my room with that sunshine smile and greet me by saying, “Good morning (or afternoon), Mr. Burrows.* You are looking better today.” She would ask how I was feeling while taking a seat at the same time, as though she were a visitor. This would make me feel as though she truly cared about my welfare. She made me feel at ease and relaxed, which helped me more easily refresh my memory. She would also explain why she was recommending each new food or drink. I also thought very highly of my nurse coordinator, Emily.* Any time I needed a question answered, she would answer it or say, “I don’t quite know the answer, but I will get it for you and call you back.” Emily was instrumental in my decision to have my last operation, which the doctor said would be very dangerous and I would have a 50-50 chance to live. Another physician informed me that it would be too dangerous, and he would not recommend this surgery for his parents. I did not want to be unable to care for myself and leave that responsibility to my wife. I decided to talk to Emily, who told me that if Dr. Morgan said he would do it, it would most likely be successful. This was all the encouragement I needed. I called the doctor and informed him that God is not through with me, so I’m ready to have the surgery whenever he would be ready. As you can see, a dead person has never written a line. After the successful surgery, Dr. Morgan spent much time at my bedside tracking my progress. I thank my excellent doctor for seven operations and five procedures. Thanks to him and his magnificent staff for a new life. * Names are fictitious. Table 1 • Loperamide hydrochloride, diphenoxylate hydrochloride and atropine sulfate, codeine, tincture of opium: Gut-slowing, antidiarrheal drugs • Ursodeoxycholic acid (Ursodiol): A form of bile acid to improve biliary flow and biochemical markers of cholestasis • Octreotide injection: Somatostatin analog to decrease gastrointestinal secretions and motility References 2. Willcutts K, Scarano K, Eddins CW. Ostomies and fistulas: a collaborative approach. Pract Gastroenterol. 2005;29(11):63-79. 3. Teubner A, Morrison K, Ravishankar HR, et al. Fistuloclycis can successfully replace parenteral feeding in the nutritional support of patients with enterocutaneous fistula. Brit J Surg. 2004;91(5):625-631. 4. Fessler T. Trace element monitoring and therapy for adult patients receiving long-term total parenteral nutrition. Pract Gastroenterol. 2005;29(3):44-65. 5. Kumpf VJ. Parenteral nutrition-associated liver disease in adult and pediatric patients. Nutr Clin Pract. 2006;21(3):279-290. 6 Matarese LE, O’Keefe SJ, Kandil HM, ey al. Short bowel syndrome: clinical guidelines for nutrition management. Nutr Clin Pract. 2005;20(5):493-502. 7. Shatsky F, Borum P. Should carnitine be added to parenteral nutrition solutions? Nutr Clin Pract. 2000;15(3):152-154. 8. Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition. 2006;22(11-12):1210-1213. 9. Kandil HM, O’Keefe SJD. Medications: Antidiarrheals, H2 blockers, proton pump inhibitors, and antisecretory therapy. In: Materese LE, Steiger E, Seidner DL, eds. Intestinal Failure and Rehabilitation. A Clinical Guide. New York: CRC Press; 2005. |
|||
| Copyright © 2010 Publishers of Today's Dietitian All rights reserved. |
Contact About Writers' Guidelines |










